(1S,2S,4R,7S,10R,11S,14S,15S)-2,4,15-trimethyl-5-oxotetracyclo[8.7.0.02,7.011,15]heptadecan-14-yl propanoate

• ChemBase编号: 736
• 分子式: C23H36O3
• 平均质量: 360.53014
• 单一同位素质量: 360.26644501
• SMILES: O([C@@H]1[C@@]2([C@H]([C@H]3[C@@H]([C@@]4([C@@H](CC3)CC(=O)[C@@H](C4)C)C)CC2)CC1)C)C(=O)CC
• Canonical SMILES: CCC(=O)O[C@H]1CC[C@@H]2[C@]1(C)CC[C@H]1[C@H]2CC[C@@H]2[C@]1(C)C[C@@H](C)C(=O)C2
• InChI: InChI=1S/C23H36O3/c1-5-21(25)26-20-9-8-17-16-7-6-15-12-19(24)14(2)13-23(15,4)18(16)10-11-22(17,20)3/h14-18,20H,5-13H2,1-4H3/t14-,15+,16+,17+,18+,20+,22+,23+/m1/s1
• InChIKey: NOTIQUSPUUHHEH-UXOVVSIBSA-N

名称和登记号

名称

• IUPAC标准名: (1S,2S,4R,7S,10R,11S,14S,15S)-2,4,15-trimethyl-5-oxotetracyclo[8.7.0.0^2,^7.0^1^1,^1^5]heptadecan-14-yl propanoate; (1S,2S,4R,7S,10R,11S,14S,15S)-2,4,15-trimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl propanoate
• IUPAC传统名: masteron; dromostanolone
• 商标名: Drolban; Emdisterone; Masterid; Masteril; Masteron; Masterone; Metholone; Permastril
• 别名: Drostanolone propionate; 2M-DHTP; 2MDTP; MDHT; Medrotestron propionate; Dromostanolone propionate; Dromostanolone proprionate; Drostanolone; Drostanolone propionate; Blackburn Compound; Dromostanolone; (1S,2S,4R,7S,10R,11S,14S,15S)-2,4,15-trimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-14-yl propanoate

登记号

• CAS号: 58-19-5
• MDL号: MFCD01669961
• PubChem SID: 160964199
• PubChem CID: 224004
• CHEBI ID: 31523
• Chemspider ID: 194604
• DrugBank ID: DB00858
• 维基百科标题: Drostanolone_propionate

理论计算性质

JChem

• 质子受体: 2
• 质子供体: 0
• LogD (pH = 5.5): 5.0959053
• LogD (pH = 7.4): 5.0959053
• Log P: 5.0959053
• 摩尔折射率: 101.956 cm^3
• 极化性: 41.01097 Å^3
• 极化表面积: 43.37 Å^2
• 可自由旋转的化学键: 3
• 里宾斯基五规则: false

ALOGPS 2.1

• Log P: 4.76
• LOG S: -5.76
• 溶解度: 6.29e-04 g/l

分子性质

理化性质

• 疏水性(logP): 5.547; 5.8

药理学性质

• 给药途径: Intramuscular injection or transdermal cream
• 生物利用度: Oral 0-2%, Intramuscular 100%
• 排泄: renal
• 半衰期: 2-3 Days
• 代谢: hepatic
• 蛋白结合率: highly
• 法定药品分级: Schedule III (US); Schedule IV (Canada)
• 妊娠期药物分类: X

产品相关信息

• 纯度: 95%

详细说明

DrugBank - DB00858

• Drug Groups: illicit; approved
• Description: Drostanolone (also known as dromostanolone) is a potent synthetic androgenic anabolic steroid similar to testosterone. Drostanolone is indicated in postmenopausal women with recurrent breast cancer, in a combined hormone therapy.
• Indication: For use in females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal.
• Pharmacology: Dromostanolone is a synthetic androgen, or male hormone, similar to testosterone. Dromostanolone works by attaching itself to androgen receptors; this causes it to interact with the parts of the cell involved in the making of proteins. It may cause an increase in the synthesis of some proteins or a decrease in the synthesis of others. These proteins have a variety of effects, including blocking the growth of some types of breast cancer cells, stimulating cells that cause male sexual characteristics, and stimulating the production of red blood cells.
• Toxicity: Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.
• Affected Organisms: Humans and other mammals
• Absorption: Well absorbed following parenteral administration.
• External Links: Wikipedia